In the current funding window where seemingly nothing can miss - the class of 2020 IPOs are up 46% from offer - and order inflation is rampant, setting the right price has become increasingly tricky. Even biotechs, whose livelihood depends on continued access to capital, are finding it tough to get the balance right between maximising proceeds and securing the requisite aftermarket pop.
展开▼
